758 results on '"Le Cesne, A."'
Search Results
2. Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs
3. VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
4. Description of Two New Philippine Genera Close to Jacobsoniella Melichar (Hemiptera: Cercopidae)
5. 62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE
6. 52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study
7. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
8. 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
9. UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?
10. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas
11. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
12. Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF)
13. Improved nationwide survival of sarcoma patients with a network of reference centers
14. Desmoid-type fibromatosis: Current Therapeutic Strategies and Future Perspectives
15. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
16. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years
17. Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review
18. ASO Visual Abstract: Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
19. Intraoperative motive for incomplete resection in primary retroperitoneal sarcoma
20. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
21. Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
22. Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
23. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
24. Overview of the role of liquid biopsy in cancer management
25. LEIOMYOSARCOMA AND LIPOSARCOMA IN YOUNG PATIENTS: THE NATIONAL NETSARC+ NETWORK EXPERIENCE
26. Patient-Reported Outcomes and Tolerability in Patients Receiving Ripretinib versus Sunitinib After Treatment with Imatinib in INTRIGUE, a Phase 3, Open-Label Study
27. Le traitement des résistances moléculaires et des sous types rares de GIST en 2023
28. Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]
29. Unsupervised classification to improve the quality of a bird song recording dataset
30. Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
31. Desmoid type fibromatosis in pediatric and young adults from French databases: Clinical characteristics and initial outcome according to age
32. Discussion à propos de la communication : « traitement par imatinib des tumeurs stromales gastro-intestinales, 20 ans après »
33. Supplementary Figure from Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
34. Supplementary Data from Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
35. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
36. Legend for supplementary Figure S1 from Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
37. Figure S1 from Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
38. Supplementary Figure 3 from Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
39. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
40. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
41. Supplementary Table 1 from Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
42. Supplementary Figure 2 from Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
43. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
44. Supplementary Data from Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis
45. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
46. Supplementary Table S1 from Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
47. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
48. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
49. Supplementary Figure 2 from Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
50. Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.